Continuous versus intermittent short-acting β2-agonists nebulization as first-line therapy in hospitalized children with severe asthma exacerbation: a propensity score matching analysis

Table 4 Pre-specified study clinical endpoints

Clinical endpoints	Continuous nebulization (n = 56)		Intermittent nebulization (n = 56)		Treatment effect (continuous vs. intermittent nebulization)
	n	%	n	%	Clinical parameters	Unadjusted analysis			Adjusted analysis^a
	n	%	n	%	Clinical parameters	Effect	95%CI	P-value	Effect	95%CI	P-value
Success	49	87.5	32	57.1	Risk difference (%)	30.4	14.6, 46.1	< 0.001	39.5	22.7, 56.3	< 0.001
					SHR	2.03	1.30, 3.17	0.002	2.70	1.72, 4.22	< 0.001
Failure	7	12.5	24	42.9	Risk difference (%)	−30.4	−46.1, −14.6	< 0.001	−39.5	−56.3, −22.7	< 0.001
					SHR	0.25	0.11, 0.58	0.001	0.12	0.05, 0.31	< 0.001
LOS (hour), mean ± SD	52.8	±28.2	59.1	±66.4	RMST difference (mean)	−2.92	−14.54, 8.70	0.623	−9.88	−24.18, 4.42	0.176

Abbreviation: LOS Length of stay; RMST Restricted mean survival time; SHR Sub-distributional hazard ratio (under competing risk time-to-event analysis).^amultivariable analysis adjusted for potential confounders (prognostic factors, treatment at emergency room, and co-medications during admission)

ISSN: 2054-7064